Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What percentage of a drug remains in the body after 3 half-lives?

12.50%. **Explanation:** The concept tested here is the **elimination kinetics** of a drug, specifically focusing on the **half-life ($t_{1/2}$)**. The half-life is the time required for the plasma concentration of a drug to be reduced by 50%. **Why 12.50% is Correct:** In first-order kinetics (followed by most drugs), a constant fraction of the drug is eliminated per unit of time. The percentage of the drug remaining follows a predictable decay pattern: * **0 Half-life:** 100% remains. * **1 Half-life:** 50% remains (50% eliminated). * **2 Half-lives:** 25% remains (50% of 50%; 75% eliminated). * **3 Half-lives:** **12.50% remains** (50% of 25%; 87.5% eliminated). **Analysis of Incorrect Options:** * **B (75%):** This represents the amount **eliminated** after 2 half-lives, not the amount remaining after 3. * **C (87.50%):** This is the total percentage of the drug **eliminated/cleared** from the body after 3 half-lives ($100 - 12.5 = 87.5$). * **D (94%):** This is the approximate percentage of the drug **eliminated** after 4 half-lives ($100 - 6.25 = 93.75$). **NEET-PG High-Yield Pearls:** 1. **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during constant-rate infusion. 2. **Complete Elimination:** For clinical purposes, a drug is considered "completely" eliminated from the body after **5 half-lives** (96.8% cleared). 3. **First-order vs. Zero-order:** In first-order kinetics, $t_{1/2}$ is constant. In zero-order kinetics (e.g., high-dose Aspirin, Phenytoin, Ethanol), a constant *amount* is eliminated, and $t_{1/2}$ is not constant. 4. **Formula:** Percentage remaining = $(1/2)^n \times 100$, where $n$ is the number of half-lives.

Q: Titration of drug dosage based on patient response is most effectively achieved with which of the following routes of administration?

Inhalation. **Explanation:** The core concept behind effective dose titration is the **rapidity of onset** and the **ability to terminate drug delivery** once the desired effect is achieved. **Why Inhalation is Correct:** The inhalation route offers a very large surface area (alveolar membrane) and high vascularity, leading to an almost instantaneous onset of action, similar to intravenous administration. More importantly, it allows for **breath-by-breath titration**. In clinical practice (e.g., volatile anesthetics like Sevoflurane), the clinician can increase or decrease the concentration of the drug in the inspired air and see an immediate change in the patient's physiological state. If an adverse effect occurs, stopping the inhalation leads to rapid elimination of the drug from the lungs. **Why Other Options are Incorrect:** * **Sublingual:** While it bypasses first-pass metabolism and has a quick onset (e.g., Nitroglycerin), once the tablet is dissolved, the dose cannot be "titrated" or withdrawn to fine-tune the response. * **Transdermal:** This route is designed for **slow, sustained release** (e.g., Fentanyl patches). It has a very long lag time to reach steady-state plasma levels, making it the least suitable for acute titration. * **Subcutaneous:** Absorption is relatively slow and depends on local blood flow. Once injected, the drug depot cannot be removed, preventing precise control over the immediate response. **High-Yield Clinical Pearls for NEET-PG:** * **Inhalation** is the fastest route for drugs to reach the brain (shorter path than IV). * **Bioavailability** of IV route is 100% by definition. * **First-pass metabolism** is bypassed by Sublingual, Transdermal, and Inhalation routes, but only partially bypassed by the Rectal route (approx. 50%).

Q: What does the clearance of a drug refer to?

All the above.. **Clearance (Cl)** is one of the most critical pharmacokinetic parameters in clinical practice. It represents the theoretical volume of plasma from which a drug is completely removed per unit of time (e.g., mL/min) [1]. 1. **Why Option A is correct:** Clearance is the quantitative measure of the body's efficiency in eliminating a drug. It is the sum of all elimination processes (Renal + Hepatic + Others). Mathematically, $Cl = ext{Rate of elimination} / ext{Plasma concentration}$ [2]. 2. **Why Option B is correct:** An organ cannot remove more drug than is delivered to it via blood. Therefore, the clearance of a drug by a specific organ (like the liver) can never exceed the blood flow to that organ ($Q$) [1]. For example, hepatic clearance cannot exceed hepatic blood flow (~1500 mL/min). 3. **Why Option C is correct:** This is a high-yield clinical concept. At steady state, the rate of drug administration equals the rate of elimination. The formula $Css = ext{Infusion rate} / Cl$ shows that clearance is the primary determinant of the **Steady-State Concentration ($C_{ss}$)** [1]. **Clinical Pearls for NEET-PG:** * **Maintenance Dose:** Clearance is the parameter used to calculate the maintenance dose ($MD = C_{ss} imes Cl$) [1]. * **Half-life ($t_{1/2}$):** Clearance is inversely proportional to half-life ($t_{1/2} = 0.693 imes Vd / Cl$). If clearance decreases (e.g., renal failure), the half-life increases. * **First-order Kinetics:** For most drugs, clearance remains constant regardless of the plasma concentration [2]. * **Zero-order Kinetics:** Clearance decreases as the plasma concentration increases (e.g., Phenytoin, Alcohol, Salicylates at high doses) [2].

Q: Arrange the following drugs according to increasing volume of distribution: 1. Haloperidol 2. Gentamicin 3. Heparin 4. Chloroquine?

3-2-1-4. **Explanation:** The **Volume of Distribution ($V_d$)** is a theoretical volume that relates the amount of drug in the body to its plasma concentration. It is determined by a drug's lipid solubility, ionization, and protein binding. 1. **Heparin ($V_d \approx 0.05$ L/kg):** Being a large, highly ionized molecule, it is confined almost entirely to the **plasma compartment**. It has the lowest $V_d$ among the options. 2. **Gentamicin ($V_d \approx 0.25$ L/kg):** As a polar/hydrophilic molecule (Aminoglycoside), it distributes into the **extracellular fluid (ECF)** but does not easily cross cell membranes. 3. **Haloperidol ($V_d \approx 15-20$ L/kg):** This is a lipophilic antipsychotic that crosses the blood-brain barrier and distributes into various tissues, resulting in a $V_d$ exceeding total body water. 4. **Chloroquine ($V_d \approx 13,000$ L/kg):** It is highly lipid-soluble and exhibits extensive **sequestration in tissues** (liver, spleen, lungs). It has one of the highest $V_d$ values in pharmacology. **Why Option B is correct:** The sequence **3 (Heparin) < 2 (Gentamicin) < 1 (Haloperidol) < 4 (Chloroquine)** correctly follows the progression from plasma-bound to ECF-bound to tissue-sequestered drugs. **Why other options are wrong:** * **Options A & C:** Incorrectly place Chloroquine before Haloperidol or Gentamicin before Heparin. * **Option D:** Incorrectly suggests Gentamicin has a lower $V_d$ than Heparin. **NEET-PG High-Yield Pearls:** * **Low $V_d$ ( 40L):** Drugs sequestered in tissues (e.g., Chloroquine, Digoxin, Amiodarone, TCAs). * **Clinical Significance:** Drugs with a high $V_d$ require a **Loading Dose** to achieve target plasma concentrations and are **not** effectively removed by hemodialysis during toxicity.

Q: When a drug binds to a receptor and causes an action opposite to that of an agonist, what is this called?

Inverse agonist. ### Explanation **1. Why "Inverse Agonist" is Correct:** In pharmacology, receptors often exhibit **constitutive activity**, meaning they produce a baseline biological response even in the absence of a ligand. An **Inverse Agonist** binds to the same receptor as an agonist but stabilizes the inactive form, thereby reducing the constitutive activity. This results in a pharmacological effect that is **directionally opposite** to that of the agonist (negative efficacy). **2. Analysis of Incorrect Options:** * **A. Complete (Full) Agonist:** Binds to the receptor and produces the maximum possible biological response (100% efficacy). * **B. Partial Agonist:** Binds to the receptor but produces a sub-maximal response, even at full receptor occupancy. It acts as an antagonist in the presence of a full agonist. * **D. Neutral Antagonist:** Binds to the receptor but has **zero intrinsic activity**. It does not produce a response of its own; it simply blocks the agonist from binding. It does not affect the constitutive activity. **3. NEET-PG High-Yield Clinical Pearls:** * **Classic Examples of Inverse Agonists:** * **Beta-carbolines** (at GABA-A receptors): Cause anxiety and convulsions (opposite to Benzodiazepines). * **Famotidine** (H2 receptors). * **Losartan** (AT1 receptors). * **Naloxone** (at Mu-opioid receptors). * **Key Distinction:** While an antagonist has **zero** efficacy, an inverse agonist has **negative** efficacy. * **Concept Check:** If a receptor has no constitutive activity, an inverse agonist will behave exactly like a neutral antagonist.

Q: When a drug binds to a receptor and causes an action opposite to that of an agonist, it is called as:

Inverse agonist. ### Explanation **Correct Answer: C. Inverse Agonist** The concept of drug-receptor interaction is based on the **Two-State Model**. Receptors exist in an equilibrium between an **inactive (Ri)** and an **active (Ra)** state. Even in the absence of a ligand, some receptors are in the Ra state, producing a baseline "constitutive activity." * **Inverse Agonists** have a higher affinity for the **inactive (Ri)** state. By binding to and stabilizing the inactive form, they reduce the constitutive activity to below-baseline levels, effectively producing an effect **opposite** to that of an agonist. * *Example:* Beta-carbolines act as inverse agonists at GABA-A receptors, causing anxiety and convulsions (opposite to the sedative effect of GABA). **Analysis of Incorrect Options:** * **A. Complete (Full) Agonist:** Binds to the active state (Ra) and produces the maximum possible biological response (100% efficacy). * **B. Partial Agonist:** Binds to both states but has a slight preference for Ra. It produces a sub-maximal response regardless of concentration and can act as an antagonist in the presence of a full agonist. * **D. Neutral Antagonist:** Has equal affinity for both Ri and Ra states. It does not change the baseline activity but prevents an agonist from binding. **High-Yield Clinical Pearls for NEET-PG:** * **Efficacy vs. Potency:** Efficacy (Intrinsic Activity) is the maximum effect a drug can produce; Potency is the amount of drug needed to produce a certain effect. * **Intrinsic Activity (α) Values:** * Full Agonist: α = 1 * Antagonist: α = 0 * Partial Agonist: α is between 0 and 1 * Inverse Agonist: α is negative (e.g., -1) * **Common Example:** Naloxone is a competitive antagonist, while many drugs previously thought to be antagonists (like Propranolol) are now classified as inverse agonists.

Q: The pharmacokinetic properties of a new drug are being studied in normal volunteers during phase I clinical trials. The volume of distribution and clearance determined in the first subject are 40 L and 2.0 L/hour, respectively. What is the approximate half-life of the drug in this subject?

14 hours. ### Explanation **1. Why Option C is Correct** The relationship between the half-life ($t_{1/2}$), volume of distribution ($V_d$), and clearance ($CL$) of a drug is defined by the following first-order kinetics formula [1]: $t_{1/2} = rac{0.693 \times V_d}{CL}$ **Calculation:** * Given $V_d = 40\text{ L}$ * Given $CL = 2.0\text{ L/hr}$ * $t_{1/2} = rac{0.693 \times 40}{2.0}$ * $t_{1/2} = 0.693 \times 20$ * $t_{1/2} = 13.86\text{ hours} \approx \mathbf{14\text{ hours}}$ The half-life is directly proportional to the volume of distribution (how widely the drug spreads in the body) and inversely proportional to the clearance (how fast the body removes the drug) [2]. **2. Why Other Options are Incorrect** * **Option A (2 hours):** This would occur if the clearance was much higher (approx. $14\text{ L/hr}$) or the $V_d$ much lower. * **Option B (6 hours):** This is a common distractor resulting from calculation errors or forgetting the $0.693$ constant. * **Option D (21 hours):** This value would be reached if the $V_d$ was $60\text{ L}$ or the clearance was reduced to $1.3\text{ L/hr}$. **3. Clinical Pearls for NEET-PG** * **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during continuous dosing. * **Elimination:** Similarly, it takes 4 to 5 half-lives for a drug to be effectively eliminated from the body (94–97% removal). * **$V_d$ and Dialysis:** Drugs with a very high $V_d$ (e.g., Digoxin, Chloroquine) are sequestered in tissues and cannot be efficiently removed by hemodialysis. * **Clearance:** This is the most important parameter in determining the **Maintenance Dose**, whereas $V_d$ determines the **Loading Dose** [3].

Q: Which of the following statements regarding Cytochrome P450 is FALSE?

Found only in bone marrow. **Explanation:** **Why Option A is the correct (False) statement:** Cytochrome P450 (CYP450) enzymes are **not** found only in the bone marrow. In fact, they are most abundantly expressed in the **liver** (the primary site of drug metabolism), followed by the enterocytes of the small intestine. While they exist in various extrahepatic tissues like the kidneys, lungs, and skin, their presence in the bone marrow is minimal and certainly not exclusive. **Analysis of other options:** * **Option B (CYP3A4 is the most common isoform):** This is true. CYP3A4 is the most abundant isoform in the liver and is responsible for metabolizing approximately 50% of all clinically used drugs. * **Option C (Participate in Phase 1 reactions):** This is true. CYP450 enzymes are the primary mediators of Phase 1 reactions, specifically **oxidation**, reduction, and hydrolysis, which aim to make drugs more polar. * **Option D (Present in Smooth Endoplasmic Reticulum):** This is true. These enzymes are membrane-bound hemoproteins located primarily in the **Smooth Endoplasmic Reticulum (SER)** of hepatocytes. When liver tissue is homogenized, these SER fragments form "microsomes," which is why they are often called microsomal enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Inducers (Increase metabolism):** Phenytoin, Rifampin, Carbamazepine, Griseofulvin, Smoking (Mnemonic: **GPRS Cell Phone**). * **Inhibitors (Decrease metabolism):** Erythromycin, Ketoconazole, Cimetidine, Valproate, Grapefruit juice (Mnemonic: **VITAMIN K**). * **Genetic Polymorphism:** Most commonly seen with **CYP2D6** (affects codeine and metoprolol metabolism). * **Non-Microsomal Enzymes:** These include Alcohol dehydrogenase, MAO, and Xanthine oxidase; unlike CYP450, these are **not** inducible.

Q: Which of the following is an ionotropic receptor?

Nicotinic cholinergic receptor. **Explanation:** Receptors are classified into four major types based on their structure and signaling mechanism. **Ionotropic receptors** (Ligand-gated ion channels) are transmembrane proteins that open or close in response to the binding of a chemical messenger, allowing the rapid flow of ions across the cell membrane. **Why Option B is Correct:** The **Nicotinic Cholinergic Receptor (nAChR)** is a classic example of an ionotropic receptor. It is a pentameric structure that, upon binding with Acetylcholine, undergoes a conformational change to open a central pore. This allows the influx of **Sodium (Na+)** and efflux of **Potassium (K+)**, leading to rapid depolarization. These are found at the neuromuscular junction (NMJ) and autonomic ganglia. **Why Other Options are Incorrect:** * **A. Muscarinic Cholinergic Receptor:** These are **G-Protein Coupled Receptors (GPCRs)** or metabotropic receptors. They act via second messengers (like IP3/DAG or cAMP) and are slower than ionotropic receptors. * **C. Glucocorticoid Receptor:** These are **Intracellular/Nuclear receptors**. They act as ligand-activated transcription factors that regulate gene expression in the nucleus. * **D. Insulin Receptor:** This is an **Enzyme-linked receptor** (specifically, a Receptor Tyrosine Kinase). Binding of insulin leads to autophosphorylation of tyrosine residues. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (milliseconds) > GPCRs (seconds) > Enzyme-linked (minutes/hours) > Nuclear receptors (hours/days). * **Other Ionotropic Examples:** GABA-A (Chloride channel), Glycine, 5-HT3 (the only ionotropic Serotonin receptor), and NMDA/AMPA receptors. * **Pharmacogenomics Link:** Mutations in the subunits of the nicotinic receptor can lead to conditions like Congenital Myasthenic Syndromes.

Question 1

What percentage of a drug remains in the body after 3 half-lives?

Accepted Answer

12.50%

Answer

75%

Answer

87.50%

Answer

94%

Question 2

Titration of drug dosage based on patient response is most effectively achieved with which of the following routes of administration?

Accepted Answer

Inhalation

Answer

Sublingual

Answer

Transdermal

Answer

Subcutaneous

Question 3

What does the clearance of a drug refer to?

Accepted Answer

All the above.

Answer

The efficacy of elimination of a drug by an organ or the whole body.

Answer

It cannot be greater than the blood flow to an organ.

Answer

It determines the steady-state drug concentration.

Question 4

Arrange the following drugs according to increasing volume of distribution: 1. Haloperidol 2. Gentamicin 3. Heparin 4. Chloroquine?

Accepted Answer

3-2-1-4

Answer

3-2-4-1

Answer

2-3-4-1

Answer

2-1-3-4

Question 5

A U-shaped dose-response curve is typically observed with which of the following?

Accepted Answer

Vitamins

Answer

Anti-cancer drugs

Answer

Steroids

Answer

Chelators

Question 6

When a drug binds to a receptor and causes an action opposite to that of an agonist, what is this called?

Accepted Answer

Inverse agonist

Answer

Complete Agonist

Answer

Partial Agonist

Answer

Neutral antagonist

Question 7

When a drug binds to a receptor and causes an action opposite to that of an agonist, it is called as:

Accepted Answer

Inverse agonist

Answer

Complete agonist

Answer

Partial agonist

Answer

Neutral agonist

Question 8

The pharmacokinetic properties of a new drug are being studied in normal volunteers during phase I clinical trials. The volume of distribution and clearance determined in the first subject are 40 L and 2.0 L/hour, respectively. What is the approximate half-life of the drug in this subject?

Accepted Answer

14 hours

Answer

2 hours

Answer

6 hours

Answer

21 hours

Question 9

Which of the following statements regarding Cytochrome P450 is FALSE?

Accepted Answer

Found only in bone marrow

Answer

CYP3A4 is the most common isoform

Answer

Participate in Phase 1 Xenobiotic reactions

Answer

They are present in Smooth Endoplasmic reticulum within cells

Question 10

Which of the following is an ionotropic receptor?

Accepted Answer

Nicotinic cholinergic receptor

Answer

Muscarinic cholinergic receptor

Answer

Glucocorticoid receptor

Answer

Insulin receptor

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?